secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001127537-23-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M
----------------------------------------------------------------------------

- Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).
- Full year 2022 revenue $53.7M, up 11% YoY; net loss $58.9M ($1.59/share).
- FY2023 revenue guidance $63-65M; gross margin 73-74%; operating expenses $112-114M.
- Drew $20M from CIBC loan on Feb 21, 2023; floating rate at Prime +1%.
- Added 17 new U.S. treatment centers in Q4, total 278; preparing for Japan launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/lung-20230222.htm
  HTML page:      https://secwatch.observer/filing/0001127537-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer